These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33973655)

  • 1. Population pharmacokinetics of raxibacumab in healthy adult subjects.
    Oosterholt SP; Della Pasqua O
    Br J Clin Pharmacol; 2021 Dec; 87(12):4718-4725. PubMed ID: 33973655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years.
    Oosterholt SP; Della Pasqua O
    Br J Clin Pharmacol; 2021 Dec; 87(12):4709-4717. PubMed ID: 33974281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.
    Skoura N; Wang-Jairaj J; Della Pasqua O; Chandrasekaran V; Billiard J; Yeakey A; Smith W; Steel H; Tan LK
    Lancet Infect Dis; 2020 Aug; 20(8):983-991. PubMed ID: 32333847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?
    Antoniu SA
    Expert Opin Investig Drugs; 2010 Jul; 19(7):909-11. PubMed ID: 20450444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raxibacumab: potential role in the treatment of inhalational anthrax.
    Kummerfeldt CE
    Infect Drug Resist; 2014; 7():101-9. PubMed ID: 24812521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
    Corey A; Migone TS; Bolmer S; Fiscella M; Ward C; Chen C; Meister G
    Toxins (Basel); 2013 Jan; 5(1):120-38. PubMed ID: 23344456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.
    Migone TS; Bolmer S; Zhong J; Corey A; Vasconcelos D; Buccellato M; Meister G
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1145-51. PubMed ID: 25487792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raxibacumab: a panacea for anthrax disease?
    Norris MH; Blackburn JK
    Lancet Infect Dis; 2020 Aug; 20(8):886-887. PubMed ID: 32333846
    [No Abstract]   [Full Text] [Related]  

  • 9. Raxibacumab.
    Mazumdar S
    MAbs; 2009; 1(6):531-8. PubMed ID: 20068396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raxibacumab for the treatment of inhalational anthrax.
    Migone TS; Subramanian GM; Zhong J; Healey LM; Corey A; Devalaraja M; Lo L; Ullrich S; Zimmerman J; Chen A; Lewis M; Meister G; Gillum K; Sanford D; Mott J; Bolmer SD
    N Engl J Med; 2009 Jul; 361(2):135-44. PubMed ID: 19587338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy.
    Rubinson L; Corey A; Hanfling D
    PLoS Curr; 2017 Jul; 9():. PubMed ID: 28856066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology and Anti-infective Role of Raxibacumab: A Novel Monoclonal Antibody for the Treatment of Anthrax.
    Singh H; Ratol S; Thangaraju P; Kumar S; Goel A
    West Indian Med J; 2016 Feb; 65(2):358-362. PubMed ID: 28358441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Passive Immunotherapy Protects against Enteric Invasion and Lethal Sepsis in a Murine Model of Gastrointestinal Anthrax.
    Huang B; Xie T; Rotstein D; Fang H; Frucht DM
    Toxins (Basel); 2015 Sep; 7(10):3960-76. PubMed ID: 26426050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration "Animal Rule".
    Tsai CW; Morris S
    Front Microbiol; 2015; 6():1320. PubMed ID: 26648915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans.
    Nagy CF; Leach TS; King A; Guttendorf R
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):652-660. PubMed ID: 29125719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.
    Subramanian GM; Cronin PW; Poley G; Weinstein A; Stoughton SM; Zhong J; Ou Y; Zmuda JF; Osborn BL; Freimuth WW
    Clin Infect Dis; 2005 Jul; 41(1):12-20. PubMed ID: 15937757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of the Efficacy of FDA-Approved
    Couse Z; Cui X; Li Y; Moayeri M; Leppla S; Eichacker PQ
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33450877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
    Deziel MR; Heine H; Louie A; Kao M; Byrne WR; Basset J; Miller L; Bush K; Kelly M; Drusano GL
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5099-106. PubMed ID: 16304178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans.
    Malkevich NV; Hopkins RJ; Bernton E; Meister GT; Vela EM; Atiee G; Johnson V; Nabors GS; Aimes RT; Ionin B; Skiadopoulos MH
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3618-25. PubMed ID: 24733473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results.
    Xu W; Ohanjanian L; Sun J; Cui X; Suffredini D; Li Y; Welsh J; Eichacker PQ
    PLoS One; 2017; 12(8):e0182879. PubMed ID: 28797061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.